A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer.
Waller
Cornelius F
CF
Abt. Innere Medizin I, Medizinische Universitatsklinik, Freiburg, Germany. cornelius.waller@uniklinik-freiburg.de
Semiglazov
Vladimir F
VF
Tjulandin
Sergei
S
Bentsion
Dmitry
D
Chan
Stephen
S
Challand
Rodeina
R